Effects of Olmesartan and Azilsartan on biomarkers of progression of CKD and arteriosclerosis in CKD patients

Trial Profile

Effects of Olmesartan and Azilsartan on biomarkers of progression of CKD and arteriosclerosis in CKD patients

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2014

At a glance

  • Drugs Azilsartan (Primary) ; Olmesartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 04 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top